Site growth

How private equity values a clinical research site

By TrialNotice · Updated
Two professionals negotiating across a glass table at dusk with city lights behind them
Short answerPrivate equity and strategic buyers usually value clinical research sites on a multiple of EBITDA. An investment bank that advises site sales reports standalone sites under $5 million EBITDA most often trade at 4x to 6x, mid sized operators at 7x to 9x, and larger differentiated networks in the low teens. Scale, backlog, margins, specialization, and proven enrollment move the multiple.
Source note: multiples come from an investment bank that advises site sales, citing Capital IQ, PitchBook, and proprietary data. Site specific multiples are rarely disclosed, so treat these as ranges, not quotes. This is not financial advice.

What are the multiples?

Site profileTypical EBITDA multiple
Standalone sites, EBITDA under $5 million4x to 6x
Mid sized operators, $5 to $10 million EBITDA7x to 9x
Mid market operators overall6x to 12x
Larger differentiated networks, $10 million plus EBITDALow teens

For comparison, broader pharma services deals showed a median of 19.8x EBITDA as of June 2025 (Objective IBV).

Why do networks get higher multiples?

Scale brings enrollment velocity and consistency. The same source notes that platforms assembled at single digit multiples often exit at mid teens valuations (Objective IBV). That gap is the economic engine of roll ups, and why buyers want independent sites.

What moves a multiple up or down?

  • Up: backlog of awarded studies, strong margins, oncology, CNS, or rare disease specialization, diversified sponsors, several investigators, technology adoption, demonstrated enrollment performance, and patient data assets.
  • Down: one dominant sponsor, dependence on one PI, compliance findings, and erratic enrollment (Objective IBV).

What recent deals show the pattern?

Velocity Clinical Research acquired Meridian Clinical Research in December 2022 to reach about 80 owned sites; Genstar invested in Flourish Research in September 2024; BayPine acquired CenExel in April 2025; THL Partners acquired Headlands Research in August 2025. Strategic acquirers accounted for nearly 90% of site deals from 2021 to mid 2025 (Objective IBV). Consolidation also has critics (Private Equity Stakeholder Project).

What raises value most for a smaller site?

Predictable enrollment. Buyers pay for revenue they can forecast, and revenue follows patients. A documented referral network with measured volume by physician is the kind of patient access a buyer can verify. See what buyers look for.

Get your study in front of the right local physicians

TrialNotice builds a physician referral pipeline around one active study. We identify relevant local physicians within driving distance of your site, send study aligned direct mail, follow up by email and LinkedIn, track engagement with recipient level QR codes, and route warm responses into your site team's workflow.

Talk to TrialNotice

Sources

  1. Objective Investment Banking and Valuation, "Valuation of Clinical Research Sites: What Buyers Look For"
  2. Private Equity Stakeholder Project, "Private equity moves into clinical trials" (November 2025)

Keep reading

Two clinical research site staff members reviewing a growth plan together in a bright office
Site growth

How to grow a clinical research site: a practical playbook

Research sites grow by building a record sponsors can verify: enrollment, startup speed, and screen failure. Here is what the data says about site growth, why sponsors reuse sites, and a six step playbook.

 Research site director presenting enrollment results to sponsor representatives across a conference table
Site growth

How research sites get more studies from sponsors and CROs

Sponsors award more studies to sites that enroll reliably, start fast, and forecast honestly. Here is how sponsors choose, why new sites face a slower path, and what a site can do to win repeat work.

 Sponsor clinical operations team reviewing site maps and performance charts on a large screen
Site growth

How sponsors and CROs select clinical trial sites

Sponsors shortlist sites with historical data and epidemiology, send feasibility questionnaires, then choose on patient access, past enrollment, and startup speed. Here is the process, how it evolved, and what it means for sites.